Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2Capecitabine 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Malignancies × MLN8054 × Clear all
NCT00652158 2013-09-23

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
44 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡